Warfarin use in atrial fibrillation patients at low risk for stroke: Analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 2, 2014, Pages 171-176

  Barnes, Geoffrey D ^a,g   Kaatz, Scott ^b   Winfield, Julia ^a   Gu, Xiaokui ^a   Haymart, Brian ^a   Kline Rogers, Eva ^a   Kozlowski, Jay ^c   Beasley, Dennis ^d   Almany, Steve ^e   Leyden, Tom ^f   Froehlich, James B ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HURLEY MEDICAL CENTER   (United States)

^c Huron Valley Sinai Hospital   (United States)

^d West Michigan Orthopaedics   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

^g NONE   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; CHADS2 score; Warfarin

Indexed keywords

WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MICHIGAN; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; WARFARIN;

EID: 84894659046     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0934-8     Document Type: Article

References (18)

1. You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest 141:e531S-e575S
2. Stecker EC (2010) Finding a balance in long-term anticoagulation therapy. Am J Manag Care 16:S278-S283
3. Lopes RD, Alexander JH, Al-Khatib SM et al (2010) Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159:331-339
4. Pengo V, Cucchini U, Denas G et al (2010) Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost 103:442-449
5. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
6. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ (2007) Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol 49:1561-1565
7. Stafford RS, Singer DE (1998) Recent national patterns of warfarin use in atrial fibrillation. Circulation 97:1231-1233
8. Zimetbaum PJ, Thosani A, Yu HT et al (2010) Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 123:446-453
9. Nieuwlaat R, Capucci A, Lip GY et al (2006) Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27:3018-3026
10. Meiltz A, Zimmermann M, Urban P, Bloch A (2008) Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace 10:674-680
11. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369-2429
12. Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257-e354
13. Barnes GD, Kaatz S, Golgotiu V et al (2012) Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)). J Thromb Thrombolysis 35(1):10-14
14. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692-694
15. Weigner MJ, Thomas LR, Patel U et al (2001) Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 110:694-702
16. Frick M, Frykman V, Jensen-Urstad M, Ostergren J, Rosenqvist M (2001) Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 24:238-244
17. Elliott DJ, Zhao L, Jasper SE, Lieber EA, Klein AL, Weintraub WS (2008) Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial. Am Heart J 156(374):e1-e6
18. Oral H, Veerareddy S, Good E et al (2004) Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol 15:920-924